Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients

DISCUSSION: Our findings underscore the impact of daratumumab-based treatment on CD34+ mobilization in a real-life, upfront plerixafor-free population of NDMM patients. Higher probability of requiring multiple apheresis occurred among daratumumab-treated patients. Interestingly, the observation that daratumumab might negatively impact BFU-E colony formation, independent of CD34+ cell count, offers novel biological perspectives. Appropriate strategies should be adopted by the Apheresis teams to mitigate these potential negative effects.PMID:38315530 | DOI:10.2450/BloodTransfus.667

Source: Blood Transfusion - February 5, 2024 Category: Hematology Authors: Arianna Zappaterra Ivan Civettini Anna Maria Cafro Laura Pezzetti Silvia Pierini Michela Anghilieri Laura Bellio Paola Bertazzoni Giovanni Grillo Periana Minga Maria L Pioltelli Emanuele Ravano Marianna Sassone Clara V Vigan ò Elisabetta B Volpato Carlo Source Type: research